AZD 8630
Alternative Names: AMG-104; AZD-8630Latest Information Update: 14 Oct 2024
Price :
$50 *
At a glance
- Originator Amgen
- Developer AstraZeneca
- Class Antiasthmatics; Immunoglobulin fragments
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
Most Recent Events
- 30 Aug 2024 Phase-II clinical trials in Asthma (Treatment-experienced) in USA (Inhalation) (NCT06529419)
- 06 Aug 2024 AstraZeneca initiates a phase I pharmacokinetics and safety trial (In volunteers) in USA (Inhalation) (NCT06531811)
- 01 Aug 2024 AstraZeneca plans a phase I pharmacokinetics and safety trial for Healthy subjects in the US (Inhalation) (NCT06531811)